A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Public ClinicalTrials.gov record NCT06868381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
Study identification
- NCT ID
- NCT06868381
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2026
- Primary completion
- Jun 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Feb 9, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304-2210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Cardiac Sarcoidosis trials
Other public records listing Cardiac Sarcoidosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06660732: Rilonacept in Subjects With Cardiac Sarcoidosis Recruiting
- NCT07604220: Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) Not yet recruiting
- NCT03593759: Cardiac Sarcoidosis Randomized Trial Recruiting
- NCT03049254: Mayo AVC Registry and Biobank Recruiting
- NCT07159074: Repurposing Tilmanocept for Cardiac Sarcoidosis Recruiting
- NCT06510894: Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06868381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2026 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06868381 live on ClinicalTrials.gov.